Abraxane Drives Growth In Potential $1bn Pancreatic Cancer Market
This article was originally published in Scrip
Executive Summary
The year-on-year growth rate of pancreatic cancer drug sales will be around 10% until peaking at around $1bn in 2023. The growth will be driven primarily by strong uptake of Celgene's Abraxane (nab-paclitaxel albumin bond) for the treatment of advanced pancreatic cancer, according to a recent forecast by Datamonitor Healthcare.
You may also be interested in...
Biomarkers For Pancreatic Cancer To Be Tested In Multi-drug Collaborative Study
Patient advocacy group is spearheading the genomics-driven trial, which will assess if stratification may finally be possible in pancreatic cancer.
NewLink’s HyperAcute Program In Limbo After Pancreatic Trial Blow-Up
Company says it is evaluating what to do with its HyperAcute vaccine candidates in various tumor types, as focus shifts toward IDO programs.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.